New funding for ALS aims to streamline research and discovery
February 08, 2013
Less than a week after the Team Gleason organization aired a public service announcement during the Super Bowl, which showed the debilitating effects of amyotrophic lateral sclerosis (ALS) or Lou Gherig's disease, CEO of Bloomberg Daniel L. Doctoroff and co-CEO of The Carlyle Group David M. Rubenstein have teamed with Bloomberg Philanthropies to provide funding that will accelerate research and discover new treatments for the disease.
Rubenstein, Doctoroff and the organization have collaboratively made a $25 million gift to launch a three-year initiative called Target ALS as part of larger research work that's already taking place at leading universities in the United States. Specifically, this funding will advance efforts by the Packard Center for ALS research at Johns Hopkins University and a New York-based foundation known as Project A.L.S.
"By coordinating and supporting the work of leading ALS scientists and engaging pharma and biotech, Target ALS provides a new way of organizing science that will hasten the development of much-needed therapies for this debilitating disease," said Dr. Zach Hall, a special consultant who was the first president of the California Institute for Regenerative Medicine among his accolades.
The stakes are high for one of the leaders of Target ALS, according to The New York Times. Doctoroff has had to watch his father and uncle develop symptoms, suffer and ultimately succumb to the devastating disease. He worries there could be a genetic predisposition that put himself and his children at risk, the source adds.
Nonprofit organizations that hope to benefit from large grant-giving opportunities can improve their chances of being selected for awards when they use nonprofit financial management programs. These solutions can generate data-driven reports for various stakeholders.